Abbott Laboratories raises full-year profit guidance, increases Q2 medical device sales by 12%, and plans to launch an OTC glucose monitor, Lingo.
Abbott Laboratories raises full-year profit guidance, with Q2 medical device sales up 12%. The company's Libre blood glucose monitor sales grow by 20.4%. Abbott plans to launch an over-the-counter glucose monitoring device, Lingo, by the end of the year, targeting health-conscious consumers without diabetes. Lingo, which received FDA clearance, has the potential to be a multi-billion-dollar product.
July 18, 2024
4 Articles